Treatment of Congenital Chylothorax in a Premature Infant using Octreotide.
- Author:
Yoon Jin AHN
1
;
You Hoon JEON
;
Sung Shin KIM
;
Jae Ock PARK
;
Chang Hwi KIM
Author Information
1. Department of Pediatrics, College of Medicine, Soonchunhyang University, Bucheon and Seoul Hospital, Korea. kimss@schbc.ac.kr
- Publication Type:Case Report
- Keywords:
Congenital;
Chylothorax;
Somatostatin;
Octreotide;
Prematurity
- MeSH:
Chyle;
Chylothorax*;
Humans;
Infant, Newborn;
Infant, Premature*;
Korea;
Octreotide*;
Pleural Effusion;
Somatostatin;
Thoracic Cavity;
Thoracic Duct;
United Nations
- From:Journal of the Korean Society of Neonatology
2006;13(2):261-266
- CountryRepublic of Korea
- Language:English
-
Abstract:
Chylothorax, defined as escape of chyle from the thoracic duct into the thoracic cavity, is the most common cause of pleural effusion during the neonatal period. The use of octreotide, a synthetic analogue of the somatostatin, for the treatment of congenital idiopathic chylothorax, has not been previously reported in Korea. We report here a case of idiopathic congenital chylothrax successfully treated with octreotide in a premature infant who showed no response to conservative therapies.
